פורמט עלון זה נקבע ע"י משרד הבריאות ותוכנו נבדק ואושר על ידו ביולי 2003
לשימוש וטרינרי בלבד
חייב מרשם רופא וטרינרי

FLUNIXIN INJECTION

פלוניקסין וטרינרי

PRESENTATION
Flunixin Veterinary is clear colourless solution for intravenous administration containing 50 mg flunixin, as flunixin meglumine USP and 5mg phenol Ph. Eur. as preservative, per ml.
In horses, flunixin may be used also as an intramuscular injection.

USES
Flunixin meglumine is a relatively potent non-narcotic, non-steroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties.
In horses, Flunixin Injection is indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders and for alleviation of visceral pain associated with colic.
In cattle, Flunixin Injection is indicated for the control of acute inflammation associated with respiratory disease.

DOSAGE AND ADMINISTRATION
Flunixin Veterinary is indicated for intravenous administration to cattle and horses.
In horses, flunixin may be used also as an intramuscular injection.

HORSES: For use in equine colic, the recommended dose ratio is 1.1 mg flunixin per kg bodyweight, by intravenous injection.
Treatment may be repeated once or twice if colic recurs.
For use in musculo-skeletal disorders, the recommended dose rate is 1.1 mg flunixin per kg bodyweight. Equivalent to 1ml per 45kg bodyweight injected intravenously once daily for up to 5 days according to clinical response. For the treatment of endotoxaemia or septic shock associated with gastric torsion and other conditions in which the circulation of blood to the gastrointestinal tract is compromised: 0.25mg/kg (1ml per 200kg) every 6-8 hours.

CATTLE: The recommended dose rate is 2.2 mg flunixin per kg bodyweight, equivalent to 2ml per 45kg bodyweight injected intravenously and repeated as necessary at 24-hour intervals for up to 5 consecutive days.

PACKAGING QUANTITIES
Multi-dose vials of 50ml and 100ml

CONTRA-INDICATIONS, WARNINGS, ETC
Do not exceed the recommended dose for the duration of treatment.
Do not administer to pregnant mares.
Monitor drug compatibility closely where adjunctive therapy is required.
Avoid intra-arterial injection.
It is preferable that NSAIDs, which inhabit prostaglandin synthesis, are not administered to animals undergoing anesthesia until fully recovered.
Non-steroidal anti-inflammatory drugs are not permitted under the rules of racing and under rules covering other competitive events. The Royal College of Veterinary Surgeons has given advice to the veterinary profession regarding the use of anti-inflammatory drugs in competing horses. It states that if a veterinarian recommends the discontinuation of any such drug not less than eight days before racing he should feel sure that he has catered for all but the most exceptional cases. The cause of the underlying inflammatory condition or colic should be determined and treated with appropriate concomitant therapy.
Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease where there is the possibility of gastro-intestinal ulceration or bleeding and when there is evidence of a blood dyscrasia or hypersensitivity to the product.
Do not administer other non-steroidal anti-inflammatory drugs (NSAIDs) concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
Use in any animal less than 5 weeks of age or in aged animals may involve an additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management.
Avoid use in dehydrated, hypovolemic or hypotensive animal, except in the case of endotoxaemia or septic shock, as there is a potential risk of increased renal toxicity.
Concurrent administration of potentially nephrotoxic drugs should be avoided.

WITHDRAWAL PERIODS
Animals must not be slaughtered for human consumption during treatment.
Cattle may be slaughtered for human consumption only after 10 days from the last treatment. Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken from treated cows after 72 hours from the last treatment.

EXICIPIENTS
Sodium Formaldehyde Sulphoxylate, Disodium Edetate, Phenol, Propylene Glycol, Diethanolamine, Hydrochloric Acid, Water for injection

PHARMACEUTICAL PRECAUTIONS
Store below 25ºC. Protect from light.
Store out of reach of children.
Following withdrawal of the first dose, use the product within 28 days. Discard unused product.

MANUFACTURER
Norbrook Laboratories Limited, Station Works, Newry, Co. Down, BT35 6JP, Northern Ireland, U.K.

REGISTRATION HOLDER
Comex Ltd P.O.Box 19943 Jerusalem

627

Client Artwork Approval - Proof 3 - Norbrook Designer: Eamon McAllister (28/10/2015)

Customer..... Comex
Country..... Jerusalem
Product ..... Flunixin Injection
Volume ..... Insert
Resource Code ..... (405)026472
Revision Level I03
Pharma Code..... 627
Barcode..... n/a
Dimensions ..... 148 x 210mm
Keyline (Die) Ref. ..... A5, Single-sided

COLOURS USED:
■ PMS Black

PLEASE READ THIS IMPORTANT INFORMATION: Please ensure this proof matches your artwork requirements. Please check all aspects of the proof i.e. text, fonts, spelling, colours, size, construction, copy position, barcodes, pharma codes, orientation of graphics etc. Mark clearly any amendments which you identify. Receiving the signed approval of this proof will authorise Norbrook Laboratories to proceed with your order. Norbrook Laboratories will not be liable for the costs of an order produced where any amendments required were not identified on the signed proof. Please return the signed approval at your earliest convenience to enable us to proceed with the order and meet your requested delivery date.

Norbrook®
Artwork Department
Station Works, Newry, Co. Down, BT35 6JP
Tel: +44 (0) 28 3026 4435
E-mail: eamon.mcallister@norbrook.co.uk

CUSTOMER APPROVAL (PLEASE SIGN)
Signature: _____
Print Name: _____
Date: _____

12/10/15 Proof1: Initial proof
14/10/15 Proof2: Customer sent new text to update the insert further.
28/10/15 Proof3: Proofreader has advised of some spelling/grammar corrections.